Exhibit 10.8 Collaboration Agreement Section 1: General Intention China Netcom of GuangXi Province ("Party A") and Beijing Candidsoft Technology Co. Ltd. ("Party B"), in accordance with People's Republic of China's Agreement Law and other regulations...Collaboration Agreement • August 6th, 2008 • China Voice Holding Corp.
Contract Type FiledAugust 6th, 2008 Company
ANDCollaboration Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Georgia
Contract Type FiledJanuary 18th, 2006 Company Industry Jurisdiction
BETWEENCollaboration Agreement • June 5th, 2007 • Transition Therapeutics Inc. • New York
Contract Type FiledJune 5th, 2007 Company Jurisdiction
EXHIBIT 10.13 COLLABORATION AGREEMENTCollaboration Agreement • March 22nd, 2005 • BioNumerik Pharmaceuticals, Inc. • Services-commercial physical & biological research
Contract Type FiledMarch 22nd, 2005 Company Industry
EXHIBIT 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Collaboration Agreement • June 24th, 2004 • Viacell Inc • Services-commercial physical & biological research • New York
Contract Type FiledJune 24th, 2004 Company Industry Jurisdiction
AMENDED AND RESTATED COLLABORATION AGREEMENTCollaboration Agreement • August 9th, 2019 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2019 Company Industry JurisdictionTHIS AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agreement”) is dated as of June 19, 2019 by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 2 Gansevoort Street, New York, NY 10014 (“CTI”), and TG Therapeutics, Inc. located at 2 Gansevoort Street, New York, NY 10014 (“TGTX”). CTI, on the one hand, and TGTX, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
Collaboration Agreement between Institute of Grassland and Environmental Research and Ceres, Inc.Collaboration Agreement • January 25th, 2012 • Ceres, Inc. • Agricultural production-crops • New York
Contract Type FiledJanuary 25th, 2012 Company Industry JurisdictionTHIS AGREEMENT is made this 1st day of April, 2007 (“Effective Date”), by and between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United States of America.
COLLABORATION AGREEMENT between PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and GEN-PROBE INCORPORATED Dated as of June 15, 2010Collaboration Agreement • November 3rd, 2010 • Gen Probe Inc • Surgical & medical instruments & apparatus • California
Contract Type FiledNovember 3rd, 2010 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into between Pacific Biosciences of California, Inc., a Delaware corporation (“PacBio”), having a place of business at 1505 Adams Drive, Menlo Park, California 94025 and Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”), having a place of business at 10210 Genetic Center Drive, San Diego, California 92121. PacBio and Gen-Probe may each sometimes be referred to herein as a “party” and collectively as the “parties.”
COLLABORATION AGREEMENTCollaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California
Contract Type FiledJanuary 8th, 2014 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 2, 2012 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and LIFE TECHNOLOGIES CORPORATION, a Delaware corporation having an address of 5791 Van Allen Way, Carlsbad, California 92008 (“Life Technologies”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • September 18th, 2006 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledSeptember 18th, 2006 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 24th day of February, 2006 (the “Effective Date”), by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having an office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”).
NOW THEREFORE this Agreement witnesses that the parties mutually covenant and agree as follows: 3 PART 1Collaboration Agreement • July 3rd, 2000 • Graftech Inc • Electrical industrial apparatus • British Columbia
Contract Type FiledJuly 3rd, 2000 Company Industry Jurisdiction
COLLABORATION AGREEMENT by and between VOYAGER THERAPEUTICS, INC. and GENZYME CORPORATION February 11, 2015Collaboration Agreement • November 6th, 2015 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledNovember 6th, 2015 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of February 11, 2015 (the “Effective Date”), is entered into by and between Voyager Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Voyager”), and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Collaboration Agreement • September 8th, 2023 • CardieX LTD • Electromedical & electrotherapeutic apparatus
Contract Type FiledSeptember 8th, 2023 Company Industry
COLLABORATION AGREEMENTCollaboration Agreement • January 8th, 2014 • Biocept Inc • Services-medical laboratories • California
Contract Type FiledJanuary 8th, 2014 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of August 17, 2011 (the “Effective Date”) by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121 (“Biocept”), and CLARIENT DIAGNOSTIC SERVICES, INC., a Delaware corporation having an address of 31 Columbia, Aliso Viejo, California 92656 (“Clarient”).
COLLABORATION AGREEMENTCollaboration Agreement • May 11th, 2015 • Ignyta, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 11th, 2015 Company Industry JurisdictionThis COLLABORATION AGREEMENT (the “Agreement”), effective as of November 3, 2006 (the “Effective Date”), is made by and between Ambit Biosciences Corporation a Delaware corporation, having a principal place of business at 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (“Ambit”), and Cephalon, Inc., a Delaware corporation, having a principal place of business at 41 Moores Road, Frazer, PA 19355 (“Cephalon”).
COLLABORATION AGREEMENTCollaboration Agreement • March 28th, 2013 • Ambit Biosciences Corp • Pharmaceutical preparations • California
Contract Type FiledMarch 28th, 2013 Company Industry JurisdictionThis Collaboration Agreement (the “Agreement”) is entered into as of September 14, 2010 (the “Effective Date”) by and between AMBIT BIOSCIENCES CORPORATION, a Delaware corporation with its principal place of business located at 4215 Sorrento Valley Blvd., San Diego, California 92121 (“Ambit”), and GENOPTIX, INC., a Delaware corporation with its principal place of business located at 1811 Aston Avenue, Carlsbad, California 92008 (“Genoptix”). Ambit and Genoptix are also herein designated individually as “Party” and collectively as “Parties.”
EXHIBIT 10.14 COLLABORATION AGREEMENT This Collaboration Agreement (the "Agreement") is dated as of February 26, 1999 by and between EXELIXIS PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 260 Littlefield...Collaboration Agreement • April 7th, 2000 • Exelixis Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledApril 7th, 2000 Company Industry Jurisdiction
ARTICLE 1 - SCOPE OF COLLABORATION; COLLABORATION ACTIVITIESCollaboration Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Delaware
Contract Type FiledSeptember 24th, 2007 Company Industry Jurisdiction
Collaboration AgreementCollaboration Agreement • February 14th, 2020 • Senmiao Technology LTD • Finance services
Contract Type FiledFebruary 14th, 2020 Company IndustryThis Collaboration Agreement (hereinafter referred to as this “Agreement”) is made and entered into by and between the following parties in Haidian District, Beijing. This Agreement may be executed in paper form offline or in electronic form through the Didi Chuxing Online Contracting Platform (website: https://contract.didichuxing.com/, hereinafter referred to as the “Contracting Platform”). The Agreement executed offline in paper form shall become effective upon the completion of the execution by both Parties (hereinafter referred to as the “Effective Date”); and the Agreement executed online in electronic form shall become effective upon the completion of the execution on the Contracting Platform by both Parties (hereinafter referred to as the “Effective Date”) recorded by the third-party online document depository.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
Contract Type FiledOctober 4th, 2013 Company Industry*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
AMENDMENT NO. 2 TO COLLABORATION AGREEMENTCollaboration Agreement • February 25th, 2005 • Adolor Corp • Pharmaceutical preparations
Contract Type FiledFebruary 25th, 2005 Company IndustryTHIS AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (this “Amendment No. 2”), dated as of December 22, 2004 (the “Effective Date”), is made by and between ADOLOR CORPORATION, a Delaware corporation and having its principal office at 700 Pennsylvania Drive, Exton, Pennsylvania 19341 (“Adolor”), and GLAXO GROUP LIMITED, a United Kingdom corporation and having its principal office at Glaxo Wellcome House, Berkely Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). Adolor and GSK are each sometimes referred to individually as a “Party” and together as the “Parties.”
COLLABORATION AGREEMENT by and among Boehringer Ingelheim International GmbH, Evotec OAIAG and Evotec Neurosciences GmbHCollaboration Agreement • March 12th, 2008 • Evotec AG • Pharmaceutical preparations
Contract Type FiledMarch 12th, 2008 Company IndustryBoehringer Ingelheim International GmbH (VAT-ID No: DE 811138149) having offices at Binger Strasse 173, 55216 Ingelheim, Germany (hereinafter referred to as “BOEHRINGER”)
RECEPTOS CONFIDENTIAL COLLABORATION AGREEMENTCollaboration Agreement • April 16th, 2013 • Receptos, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 16th, 2013 Company Industry JurisdictionThis Collaboration Agreement (the “Agreement”) is made as of December 20, 2010 (the “Effective Date”) by and between Receptos, Inc., a Delaware corporation (“Receptos”) located at 10835 Road to the Cure, Suite #205, San Diego, California 92121 and Eli Lilly and Company, an Indiana corporation (“Lilly”) having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 USA.
COLLABORATION AGREEMENTCollaboration Agreement • December 3rd, 2014 • Cardax, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 3rd, 2014 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (“Agreement”) is made as of this 18th day of August 2014 (the “Effective Date”), by and between Capsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 (“CAPSUGEL”) and Cardax, Inc., and its Affiliates, with a corporate address at 2800 Woodlawn Dr., Suite 129, Honolulu, HI 96822 (“CARDAX”). CARDAX and CAPSUGEL are each a “Party” and together constitute the “Parties”
BETWEEN MYISCO SDN BHDCollaboration Agreement • January 19th, 2024 • TETE Technologies Inc • Services-business services, nec
Contract Type FiledJanuary 19th, 2024 Company Industry
COLLABORATION AGREEMENTCollaboration Agreement • April 16th, 2013 • Receptos, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 16th, 2013 Company Industry JurisdictionThis Collaboration Agreement (the “Agreement”) is made as of December 5, 2011 (the “Effective Date”) by and between Receptos, Inc. (“Receptos”), a Delaware corporation located at 10835 Road to the Cure, Suite #205, San Diego, California 92121, USA and Ono Pharmaceutical Co., Ltd. (“ONO”), a corporation organized under the laws of Japan, having its principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan.
COLLABORATION AGREEMENTCollaboration Agreement • November 23rd, 2009 • Ecology Coatings, Inc. • Wholesale-industrial machinery & equipment • Virginia
Contract Type FiledNovember 23rd, 2009 Company Industry JurisdictionThe Agreement is by and between Reynolds Innovations Inc. (hereinafter “RII”) and Ecology Coatings Inc. (hereinafter “Supplier”). The effective date of this Agreement is April 1st, 2009.
COLLABORATION AGREEMENT dated June 15, 2010 by and between Abbott International Luxembourg S.à r.l. and Neurocrine Biosciences, Inc.Collaboration Agreement • May 5th, 2021 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 5th, 2021 Company IndustryCOLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated as of June 15, 2010 (“Effective Date”) by and between Abbott International Luxembourg S.à r.l., a corporation organized and existing under the laws of Luxembourg, with offices at 26, Boulevard Royal, L-2449 Luxembourg (“ Abbott ”) and Neurocrine Biosciences, Inc., a corporation organized and existing under the laws of Delaware with offices at 12780 El Camino Real, San Diego, California 92130 (“ Neurocrine ”).
COLLABORATION AGREEMENT by and between SURFACE ONCOLOGY, INC. and NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.Collaboration Agreement • March 23rd, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 23rd, 2018 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (this “Agreement”), entered into as of January 9, 2016 (the “Effective Date”), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”). Surface and Novartis are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT MONSANTO COMPANY and EVOGENE LTD. October 27, 2013Collaboration Agreement • November 19th, 2013 • Evogene Ltd. • Agricultural chemicals • New York
Contract Type FiledNovember 19th, 2013 Company Industry JurisdictionThis SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (“Agreement”), dated October 27 2013, by and between Monsanto Company, a Delaware corporation (“Monsanto”), and Evogene Ltd., an Israeli company (“Evogene”), shall be effective as of the 2013 Signing Date.
CONFIDENTIAL PROVISIONS REDACTED COLLABORATION AGREEMENTCollaboration Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • California
Contract Type FiledDecember 4th, 2008 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of September 12, 2005 (the “Effective Date”) by and between Protein Design Labs, Inc., a Delaware corporation having its offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”), and Biogen Idec MA Inc., a Massachusetts corporation having offices at 14 Cambridge Center, Cambridge, Massachusetts 02142 (“Biogen Idec”). PDL and Biogen Idec may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
EXHIBIT 10.10 COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (the "Agreement") is entered into as of May 2, 1998 (the "Effective Date"), by and between CALIPER TECHNOLOGIES CORP., a corporation organized under the laws of the State of Delaware...Collaboration Agreement • December 14th, 1999 • Caliper Technologies Corp • Laboratory analytical instruments • California
Contract Type FiledDecember 14th, 1999 Company Industry Jurisdiction
SECOND RESTATED COLLABORATION AGREEMENTCollaboration Agreement • March 12th, 2010 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledMarch 12th, 2010 Company Industry JurisdictionTHIS SECOND RESTATED COLLABORATION AGREEMENT (this “Agreement”), dated as of April 12, 2004, the “Revision Date”, is made between ABGENIX, INC., a Delaware corporation (“ABX”), having a place of business at 7601 Dumbarton Circle, Fremont, California 94555, and CURAGEN CORPORATION, a Delaware corporation (“CuraGen”), having a place of business at 555 Long Wharf Drive, New Haven, Connecticut 06511, with respect to the following facts:
1 EXHIBIT 10.4 [NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THESE PORTIONS HAVE BEEN MARKED WITH THE CLAUSE "CONFIDENTIAL TREATMENT REQUESTED"...Collaboration Agreement • August 14th, 2001 • Decode Genetics Inc • Services-commercial physical & biological research • New Jersey
Contract Type FiledAugust 14th, 2001 Company Industry Jurisdiction
EXHIBIT 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Collaboration Agreement • May 25th, 2004 • Viacell Inc • Services-commercial physical & biological research • New York
Contract Type FiledMay 25th, 2004 Company Industry Jurisdiction